Subtopic Deep Dive
Eicosanoid Metabolism in Cardiovascular Inflammation
Research Guide
What is Eicosanoid Metabolism in Cardiovascular Inflammation?
Eicosanoid metabolism in cardiovascular inflammation encompasses the enzymatic conversion of arachidonic acid into prostaglandins, leukotrienes, and epoxyeicosatrienoic acids (EETs) that drive monocyte activation, plaque formation, and vascular inflammatory responses in hypertension and heart disease.
Arachidonic acid metabolites like prostaglandins sustain inflammation via cyclooxygenase pathways (Ricciotti and FitzGerald, 2011, 3607 citations). Omega-3 derived resolvins and eicosanoids counterbalance pro-inflammatory signals in exudates (Serhan et al., 2002, 1613 citations). Over 10 high-citation papers detail lipidomic shifts in cardiovascular contexts.
Why It Matters
Modulating eicosanoid balance via omega-3 fatty acids reduces sudden cardiac death post-myocardial infarction, as shown in GISSI-Prevenzione trial data (Marchioli et al., 2002, 1303 citations). NSAIDs targeting cyclooxygenase inhibit prostaglandin-driven vascular damage but risk organ toxicity (Bindu et al., 2020, 1711 citations). Omega-3 eicosanoids suppress leukocyte chemotaxis in endothelial inflammation, offering pharmacological targets for hypertension (Calder, 2012, 1284 citations; Wall et al., 2010, 1085 citations).
Key Research Challenges
Dynamic Lipidomic Profiling
Capturing real-time shifts in eicosanoid profiles during monocyte-to-macrophage transition in plaques requires advanced mass spectrometry. Dennis and Norris (2015, 1422 citations) highlight eicosanoid storms in inflammation, but temporal resolution remains limited. Standardization across disease states hinders reproducibility.
Pro- vs Anti-Inflammatory Balance
Balancing COX-derived prostaglandins with resolvin pathways in vascular endothelium is complicated by context-dependent effects (Ricciotti and FitzGerald, 2011, 3607 citations). Serhan et al. (2002, 1613 citations) describe aspirin-triggered resolvins, yet therapeutic dosing varies. Cross-talk with omega-3 metabolism adds complexity (Calder, 2012).
Translational Pharmacology Gaps
Translating fish oil omega-3 benefits from trials like GISSI-Prevenzione to hypertension models faces bioavailability issues (Marchioli et al., 2002, 1303 citations). Wang et al. (2021, 1243 citations) map arachidonic pathways, but human plaque eicosanoid inhibitors lack validation. NSAID organ damage limits chronic use (Bindu et al., 2020).
Essential Papers
Prostaglandins and Inflammation
Emanuela Ricciotti, Garret A. FitzGerald · 2011 · Arteriosclerosis Thrombosis and Vascular Biology · 3.6K citations
Prostaglandins are lipid autacoids derived from arachidonic acid. They both sustain homeostatic functions and mediate pathogenic mechanisms, including the inflammatory response. They are generated ...
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Samik Bindu, Somnath Mazumder, Uday Bandyopadhyay · 2020 · Biochemical Pharmacology · 1.7K citations
Resolvins
Charles N. Serhan, Song Hong, Karsten Gronert et al. · 2002 · The Journal of Experimental Medicine · 1.6K citations
Aspirin (ASA) is unique among current therapies because it acetylates cyclooxygenase (COX)-2 enabling the biosynthesis of R-containing precursors of endogenous antiinflammatory mediators. Here, we ...
Eicosanoid storm in infection and inflammation
Edward A. Dennis, Paul C. Norris · 2015 · Nature reviews. Immunology · 1.4K citations
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction
Roberto Marchioli, Federica Barzi, Elena Bomba et al. · 2002 · Circulation · 1.3K citations
Background — Our purpose was to assess the time course of the benefit of n-3 polyunsaturated fatty acids (PUFAs) on mortality documented by the GISSI-Prevenzione trial in patients surviving a recen...
Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
Philip C. Calder · 2012 · British Journal of Clinical Pharmacology · 1.3K citations
Eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ) are n‐3 fatty acids found in oily fish and fish oil supplements. These fatty acids are able to inhibit partly a number of aspects of i...
Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits
Fereidoon Shahidi, Priyatharini Ambigaipalan · 2018 · Annual Review of Food Science and Technology · 1.3K citations
Omega-3 polyunsaturated fatty acids (PUFAs) include α-linolenic acid (ALA; 18:3 ω-3), stearidonic acid (SDA; 18:4 ω-3), eicosapentaenoic acid (EPA; 20:5 ω-3), docosapentaenoic acid (DPA; 22:5 ω-3),...
Reading Guide
Foundational Papers
Start with Ricciotti and FitzGerald (2011, 3607 citations) for prostaglandin basics in inflammation; Serhan et al. (2002, 1613 citations) for resolvin discovery; Calder (2012, 1284 citations) for omega-3 mechanisms in vascular contexts.
Recent Advances
Wang et al. (2021, 1243 citations) maps arachidonic pathways as therapeutic targets; Bindu et al. (2020, 1711 citations) details NSAID organ risks in eicosanoid modulation.
Core Methods
Cyclooxygenase inhibition for prostaglandins (Ricciotti and FitzGerald, 2011); lipidomics for eicosanoid storms (Dennis and Norris, 2015); n-3 PUFA supplementation trials (Marchioli et al., 2002).
How PapersFlow Helps You Research Eicosanoid Metabolism in Cardiovascular Inflammation
Discover & Search
Research Agent uses citationGraph on Ricciotti and FitzGerald (2011) to map prostaglandin pathways connected to 3607 citing papers, then exaSearch for 'EETs monocyte activation plaque hypertension' to uncover 50+ related works on lipidomics shifts. findSimilarPapers expands to omega-3 eicosanoids from Serhan et al. (2002).
Analyze & Verify
Analysis Agent applies readPaperContent to parse lipidomic data in Dennis and Norris (2015), then runPythonAnalysis with pandas to quantify eicosanoid ratios from extracted tables, verified by CoVe chain-of-verification. GRADE grading scores evidence strength for Marchioli et al. (2002) trial data on omega-3 cardioprotection.
Synthesize & Write
Synthesis Agent detects gaps in resolvin translation from Serhan et al. (2002) to hypertension plaques, flags contradictions between NSAID risks (Bindu et al., 2020) and omega-3 benefits (Calder, 2012). Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations to integrate 10 foundational papers, and latexCompile for publication-ready reviews; exportMermaid visualizes COX vs lipoxygenase cascades.
Use Cases
"Analyze eicosanoid ratios in plaque inflammation from omega-3 trials"
Research Agent → searchPapers 'eicosanoid lipidomics cardiovascular' → Analysis Agent → runPythonAnalysis (NumPy/pandas on Marchioli et al. 2002 tables) → matplotlib plots of PGE2:EET ratios with statistical p-values.
"Draft review on prostaglandin inhibitors in hypertension inflammation"
Synthesis Agent → gap detection on Ricciotti 2011 + Bindu 2020 → Writing Agent → latexEditText (metabolism section) → latexSyncCitations (10 papers) → latexCompile → PDF with figure legends on COX pathways.
"Find lipidomics code for eicosanoid storm analysis"
Research Agent → searchPapers 'eicosanoid storm Dennis 2015' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on shared mass spec pipelines for metabolomics verification.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'EETs prostaglandins cardiovascular inflammation', structures report with GRADE-scored sections on omega-3 mechanisms from Calder (2012). DeepScan applies 7-step CoVe to verify eicosanoid storm claims in Dennis and Norris (2015), checkpointing lipid profiles. Theorizer generates hypotheses on resolvin-NSAID combos from Serhan et al. (2002) and Bindu et al. (2020).
Frequently Asked Questions
What defines eicosanoid metabolism in cardiovascular inflammation?
It involves arachidonic acid conversion via COX, LOX, and CYP enzymes into prostaglandins, leukotrienes, and EETs that regulate monocyte activation and plaque formation (Ricciotti and FitzGerald, 2011; Wang et al., 2021).
What are key methods for studying eicosanoid pathways?
Lipidomic analysis of exudates detects aspirin-triggered resolvins (Serhan et al., 2002); mass spectrometry profiles storms in inflammation (Dennis and Norris, 2015); clinical trials assess omega-3 effects post-infarction (Marchioli et al., 2002).
What are the most cited papers?
Ricciotti and FitzGerald (2011, 3607 citations) on prostaglandins; Bindu et al. (2020, 1711 citations) on NSAID damage; Serhan et al. (2002, 1613 citations) on resolvins.
What open problems exist?
Challenges include dynamic profiling of eicosanoid shifts in plaques, balancing pro/anti-inflammatory signals, and translating omega-3 benefits to hypertension pharmacology without NSAID toxicity (Dennis and Norris, 2015; Wang et al., 2021).
Research Eicosanoids and Hypertension Pharmacology with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Eicosanoid Metabolism in Cardiovascular Inflammation with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers